HIV-1 protease inhibitors for treatment of visceral leishmaniasis in HIV-co-infected individuals

The Lancet Infectious Diseases

Volumn 13, Issue 3, 2013, Pages 251-259

  Van Griensven, Johan ^a   Diro, Ermias ^a,b   Lopez Velez, Rogelio ^c   Boelaert, Marleen ^a   Lynen, Lutgarde ^a   Zijlstra, Ed ^d   Dujardin, Jean Claude ^a   Hailu, Asrat ^e  

^a INSTITUTE OF TROPICAL MEDICINE   (Belgium)

^b UNIVERSITY OF GONDAR   (Ethiopia)

^c HOSPITAL RAMÓN Y CAJAL   (Spain)

^d Rotterdam Centre for Tropical Medicine   (Netherlands)

^e ADDIS ABABA UNIVERSITY   (Ethiopia)

Author keywords

[No Author keywords available]

Indexed keywords

AMPRENAVIR; ATAZANAVIR; ATAZANAVIR PLUS RITONAVIR; DARUNAVIR; FOSAMPRENAVIR; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; INDINAVIR; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; SAQUINAVIR; TIPRANAVIR;

ANTIRETROVIRAL THERAPY; ANTIVIRAL THERAPY; DRUG EFFICACY; DRUG TOLERABILITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IC 50; MIXED INFECTION; NONHUMAN; PRIORITY JOURNAL; REVIEW; TREATMENT FAILURE; TREATMENT RESPONSE; VISCERAL LEISHMANIASIS;

ANTIVIRAL AGENTS; COINFECTION; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; LEISHMANIA; LEISHMANIASIS, VISCERAL;

EID: 84874265447     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(12)70348-1     Document Type: Review

References (59)

1. van Griensven J, Diro E Visceral leishmaniasis. Infect Dis Clin North Am 2012, 26:309-322.
2. van Griensven J, Balasegaram M, Meheus F, et al. Combination therapy for visceral leishmaniasis. Lancet Infect Dis 2010, 10:184-194.
3. Alvar J, Velez ID, Bern C, et al. Leishmaniasis worldwide and global estimates of its incidence. PloS One 2012, 7:e35671.
4. Alvar J, Aparicio P, Aseffa A, et al. The relationship between leishmaniasis and AIDS: the second 10 years. Clin Microbiol Rev 2008, 21:334-359.
5. Ritmeijer K, Dejenie A, Assefa Y, et al. A comparison of miltefosine and sodium stibogluconate for treatment of visceral leishmaniasis in an Ethiopian population with high prevalence of HIV infection. Clin Infect Dis 2006, 43:357-364.
6. Sinha PK, van Griensven J, Pandey K, et al. Liposomal amphotericin B for visceral leishmaniasis in human immunodeficiency virus-coinfected patients: 2-year treatment outcomes in Bihar, India. Clin Infect Dis 2011, 53:e91-e98.
7. Ritmeijer K, Ter Horst R, Chane S, et al. Limited effectiveness of high-dose liposomal amphotericin B (AmBisome) for treatment of visceral leishmaniasis in an Ethiopian population with high HIV prevalence. Clin Infect Dis 2011, 53:e152-e158.
8. Ter Horst R, Collin SM, Ritmeijer K, Bogale A, Davidson RN Concordant HIV infection and visceral leishmaniasis in Ethiopia: the influence of antiretroviral treatment and other factors on outcome. Clin Infect Dis 2008, 46:1702-1709.
9. Pozio E, Morales MA The impact of HIV-protease inhibitors on opportunistic parasites. Trends Parasitol 2005, 21:58-63.
10. Valdivieso E, Rangel A, Moreno J, et al. Effects of HIV aspartyl-proteinase inhibitors on Leishmania sp. Exp Parasitol 2010, 126:557-563.
11. Savoia D, Allice T, Tovo PA Antileishmanial activity of HIV protease inhibitors. Int J Antimicrob Agents 2005, 26:92-94.
12. Trudel N, Garg R, Messier N, Sundar S, Ouellette M, Tremblay MJ Intracellular survival of Leishmania species that cause visceral leishmaniasis is significantly reduced by HIV-1 protease inhibitors. J Infect Dis 2008, 198:1292-1299.
13. Achan J, Kahuru A, IkileziG, et al. Significant reduction in risk of malaria among HIV+ children receiving lopinavir/ritonavir-based ART compared to NNRTI-based ART, a randomized open-label trial. 19th Conference on Retroviruses and Opportunistic Infections (CROI); Seattle, WA, USA; March 5-8, 2012. Abstract 26.
14. De Clercq E Anti-HIV drugs: 25 compounds approved within 25 years after the discovery of HIV. Int J Antimicrob Agents 2009, 33:307-320.
15. Wensing AM, van Maarseveen NM, Nijhuis M Fifteen years of HIV protease inhibitors: raising the barrier to resistance. Antiviral Res 2010, 85:59-74.
16. Mastrolorenzo A, Rusconi S, Scozzafava A, Barbaro G, Supuran CT Inhibitors of HIV-1 protease: current state of the art 10 years after their introduction. From antiretroviral drugs to antifungal, antibacterial and antitumor agents based on aspartic protease inhibitors. Curr Med Chem 2007, 14:2734-2748.
17. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach, 2006 Revision 2006, WHO, World Health Organization, Geneva.
18. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach, 2010 Revision 2010, WHO, World Health Organization, Geneva.
19. Oldfield V, Plosker GL Lopinavir/ritonavir: a review of its use in the management of HIV infection. Drugs 2006, 66:1275-1299.
20. Scaling up antiretroviral therapy in resource-limited settings: treatment guidelines for a public health approach, 2003 revision 2004, WHO, World Health Organization, Geneva.
21. Kumar P, Lodge R, Trudel N, Ouellet M, Ouellette M, Tremblay MJ Nelfinavir, an HIV-1 protease inhibitor, induces oxidative stress-mediated, caspase-independent apoptosis in leishmania amastigotes. PLoS Negl Trop Dis 2010, 4:e642.
22. Santos LO, Vitorio BS, Branquinha MH, e Silva CMP, Santos ALS, d'Avila-Levy CM Nelfinavir is effective in inhibiting the multiplication and aspartic peptidase activity of Leishmania species, including strains obtained from HIV-positive patients. J Antimicrob Chemother 2012, published online Oct 28. 10.1093/jac/dks410.
23. Santos LO, Marinho FA, Altoe EF HIV aspartyl peptidase inhibitors interfere with cellular proliferation, ultrastructure and macrophage infection of Leishmania amazonensis. PLoS One 2009, 4:e4918.
24. Demarchi IG, Silveira TG, Ferreira IC, Lonardoni MV Effect of HIV protease inhibitors on New World Leishmania. Parasitol Int 2012, 61:538-544.
25. White RE, Powell DJ, Berry C HIV proteinase inhibitors target the Ddi1-like protein of leishmania parasites. FASEB J 2011, 25:1729-1736.
26. Vermeersch M, da Luz RI, Tote K, Timmermans JP, Cos P, Maes L In vitro susceptibilities of Leishmania donovani promastigote and amastigote stages to antileishmanial reference drugs: practical relevance of stage-specific differences. Antimicrob Agents Chemother 2009, 53:3855-3859.
27. Dash C, Kulkarni A, Dunn B, Rao M Aspartic peptidase inhibitors: implications in drug development. Crit Rev Biochem Mol Biol 2003, 38:89-119.
28. Krylov DM, Koonin EV A novel family of predicted retroviral-like aspartyl proteases with a possible key role in eukaryotic cell cycle control. Curr Biol 2001, 11:584-587.
29. Sirkis R, Gerst JE, Fass D Ddi1, a eukaryotic protein with the retroviral protease fold. J Mol Biol 2006, 364:376-387.
30. Perteguer MJ, Gomez-Puertas P, Canavate C, Dagger F, Garate T, Valdivieso E Ddi1-like protein from Leishmania major is an active aspartyl proteinase. Cell Stress Chaperones 2012, published online Aug 30. 10.1007/s12192-012-0368-9.
31. Vanaerschot M, Maes I, Ouakad M, et al. Linking in vitro and in vivo survival of clinical Leishmania donovani strains. PLoS One 2010, 5:e12211.
32. Decuypere S, Vanaerschot M, Brunker K, et al. Molecular mechanisms of drug resistance in natural leishmania populations vary with genetic background. PLoS Negl Trop Dis 2012, 6:e1514.
33. Moreira W, Leprohon P, Ouellette M Tolerance of drug-induced cell death favours the acquisition of multidrug resistance in leishmania. Cell Death Dis 2011, 2:e201-e208.
34. Den Boer M, Rivas L, Alvar J Co-infection with HIV. Drug resistance in leishmania parasites. Consequences, molecular mechanisms and possible treatments 2012, 167-182. Springer, Vienna. A. Ponte-Sucre, E. Diaz, M. Padron-Nieves (Eds.).
35. Piccinini M, Rinaudo MT, Chiapello N, et al. The human 26S proteasome is a target of antiretroviral agents. AIDS 2002, 16:693-700.
36. Robertson CD The Leishmania mexicana proteasome. Mol Biochem Parasitol 1999, 103:49-60.
37. Christensen CB, Jorgensen L, Jensen AT, et al. Molecular characterization of a Leishmania donovanii cDNA clone with similarity to human 20S proteasome a-type subunit. Biochim Biophys Acta 2000, 1500:77-87.
38. Andre P, Groettrup M, Klenerman P, et al. An inhibitor of HIV-1 protease modulates proteasome activity, antigen presentation, and T cell responses. Proc Natl Acad Sci USA 1998, 95:13120-13124.
39. Deeks SG Protease inhibitors as immunomodulatory drugs for HIV infection. Clin Pharmacol Ther 2007, 82:248-250.
40. Vlahakis SR, Bennett SA, Whitehead SN, Badley AD HIV protease inhibitors modulate apoptosis signaling in vitro and in vivo. Apoptosis 2007, 12:969-977.
41. Vlahakis SR, Bren GD, Algeciras-Schimnich A, et al. Flying in the face of resistance: antiviral-independent benefit of HIV protease inhibitors on T-cell survival. Clin Pharmacol Ther 2007, 82:294-299.
42. Gruber A, Wheat JC, Kuhen KL, Looney DJ, Wong-Staal F Differential effects of HIV-1 protease inhibitors on dendritic cell immunophenotype and function. J Biol Chem 2001, 276:47840-47843.
43. Bugelski PJ, Kaplan JM, Hart TK, et al. Effect of a human immunodeficiency virus protease inhibitor on human monocyte function. AIDS Res Hum Retroviruses 1992, 8:1951-1958.
44. Riddler SA, Haubrich R, DiRienzo AG, et al. Class-sparing regimens for initial treatment of HIV-1 infection. N Engl J Med 2008, 358:2095-2106.
45. MacArthur RD, Novak RM, Peng G, et al. A comparison of three highly active antiretroviral treatment strategies consisting of non-nucleoside reverse transcriptase inhibitors, protease inhibitors, or both in the presence of nucleoside reverse transcriptase inhibitors as initial therapy (CPCRA 058 FIRST Study): a long-term randomised trial. Lancet 2006, 368:2125-2135.
46. Del Giudice P, Mary-Krause M, Pradier C, et al. Impact of highly active antiretroviral therapy on the incidence of visceral leishmaniasis in a French cohort of patients infected with human immunodeficiency virus. J Infect Dis 2002, 186:1366-1370.
47. Villanueva JL, Alarcon A, Bernabeu-Wittel M, et al. Prospective evaluation and follow-up of European patients with visceral leishmaniasis and HIV-1 coinfection in the era of highly active antiretroviral therapy. Eur J Clin Microbiol Infect Dis 2000, 19:798-901.
48. De La Rosa R, Pineda JA, Delgado J, et al. Influence of highly active antiretroviral therapy on the outcome of subclinical visceral leishmaniasis in human immunodeficiency virus-infected patients. Clin Infect Dis 2001, 32:633-635.
49. de La Rosa R, Pineda JA, Delgado J, et al. Incidence of and risk factors for symptomatic visceral leishmaniasis among human immunodeficiency virus type 1-infected patients from Spain in the era of highly active antiretroviral therapy. J Clin Microbiol 2002, 40:762-767.
50. Casado JL, Lopez-Velez R, Pintado V, et al. Relapsing visceral leishmaniasis in HIV-infected patients undergoing successful protease inhibitor therapy. Eur J Clin Microbiol Infect Dis 2001, 20:202-205.
51. Alfonso Y, Monzote L HIV protease inhibitors: effect on the opportunistic protozoan parasites. Open Med Chem J 2011, 5:40-50.
52. Cassone A, Tacconelli E, De Bernardis F, et al. Antiretroviral therapy with protease inhibitors has an early, immune reconstitution-independent beneficial effect on candida virulence and oral candidiasis in human immunodeficiency virus-infected subjects. J Infect Dis 2002, 185:188-195.
53. Skinner-Adams TS, Butterworth AS, Porter KA, et al. The frequency of malaria is similar among women receiving either lopinavir/ritonavir or nevirapine-based antiretroviral treatment. PLoS One 2012, 7:e34399.
54. Porter KA, Cole SR, Eron JJ, et al. HIV-1 protease inhibitors and clinical malaria: a secondary analysis of the AIDS Clinical Trials Group A5208 study. Antimicrob Agents Chemother 2012, 56:995-1000.
55. Rajasingham R, Meya DB, Boulware DR Integrating cryptococcal antigen screening and pre-emptive treatment into routine HIV care. J Acquir Immune Defic Syndr 2012, 59:e85-e91.
56. Hommel M, Sarkari B, Carney J, Chance ML Katex for the diagnosis of human visceral leishmaniasis. Med Trop 2001, 61:503-505.
57. McKerrow JH, Rosenthal PJ, Swenerton R, Doyle P Development of protease inhibitors for protozoan infections. Curr Opin Infect Dis 2008, 21:668-672.
58. Silva-Lopez RE, Morgado-Diaz JA, Chavez MA, Giovanni-De-Simone S Effects of serine protease inhibitors on viability and morphology of Leishmania (Leishmania) amazonensis promastigotes. Parasitol Res 2007, 101:1627-1635.
59. Williams RA, Tetley L, Mottram JC, Coombs GH Cysteine peptidases CPA and CPB are vital for autophagy and differentiation in Leishmania mexicana. Mol Microbiol 2006, 61:655-674.